Regardless of the mechanisms of these changes (acquisition of new HIF-1α-dependent functional properties by tumor cells or enhancement of resistant clones), the cytological substrate that implements adaptation to antiangiogenic therapy is, first of all, the fraction of hypoxic tumor cells. Here, HIF1A is linked to neoplasm.